Myung In Pharm Co

Myung In Pharm Co EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Myung In Pharm Co (317450.KS) as of Nov 18, 2026 is 18.60. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 12.17 — a change of 52.80% (higher).

EV/FCF

18.60

YoY

52.80%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Myung In Pharm Co is 2025 18.60 . EV/FCF (Enterprise Value to Free Cash Flow) of Myung In Pharm Co was 2024 12.17 . It decreases by 52.80% higher compared to the previous year.

The Myung In Pharm Co EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2022
11.89 KRW
Jan 1, 2023
12.17 KRW
Jan 1, 2025
18.60 KRW
The Myung In Pharm Co EV/FCF history
YEAREV/FCFYoY
18.60+52.80%
12.17+2.35%
11.89—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Myung In Pharm Co Stock analysis

What does Myung In Pharm Co do? Myung In Pharm Co., Ltd. generates revenue through the manufacture and sale of prescription drugs for neurology and psychiatry, including stroke and Parkinson’s disease treatments, schizophrenia, and depression therapies. The company primarily targets domestic and overseas markets, distributing its products under its own brand for neurological and psychiatric conditions. General pharmaceuticals such as dental, oral, digestive system treatments, and other related products form additional revenue streams within its domestic and international sales channels. The firm focuses on prescription drug segments, with key products addressing stroke, Parkinson’s disease, schizophrenia, and depression. These treatments are sold directly to healthcare providers and pharmacies in both domestic and overseas markets. The company also offers general pharmaceuticals like dental and oral treatments, alongside digestive system therapies, contributing to its diversified product portfolio across multiple therapeutic areas. Myung In Pharm’s business model relies on selling branded prescription medications for specific neurological and psychiatric conditions, alongside general pharmaceuticals. Its domestic and overseas market presence ensures consistent revenue from both regional and global healthcare sectors, with no additional details on specific customer segments or pricing strategies disclosed in the provided description. Myung In Pharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Myung In Pharm Co stock

EV/FCF (Enterprise Value to Free Cash Flow) of Myung In Pharm Co is 18.60 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Myung In Pharm Co changed from 12.17 to 18.60, representing a 52.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Myung In Pharm Co since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Myung In Pharm Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Myung In Pharm Co

All Key Metrics — Myung In Pharm Co